IL154583A0 - Active agent delivery systems and methods for protecting and administering active agents - Google Patents

Active agent delivery systems and methods for protecting and administering active agents

Info

Publication number
IL154583A0
IL154583A0 IL15458301A IL15458301A IL154583A0 IL 154583 A0 IL154583 A0 IL 154583A0 IL 15458301 A IL15458301 A IL 15458301A IL 15458301 A IL15458301 A IL 15458301A IL 154583 A0 IL154583 A0 IL 154583A0
Authority
IL
Israel
Prior art keywords
protecting
methods
delivery systems
agent delivery
administering
Prior art date
Application number
IL15458301A
Other languages
English (en)
Original Assignee
New River Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New River Pharmaceuticals Inc filed Critical New River Pharmaceuticals Inc
Publication of IL154583A0 publication Critical patent/IL154583A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15458301A 2000-08-22 2001-08-22 Active agent delivery systems and methods for protecting and administering active agents IL154583A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/642,820 US6716452B1 (en) 2000-08-22 2000-08-22 Active agent delivery systems and methods for protecting and administering active agents
PCT/US2001/026142 WO2002034237A1 (en) 2000-08-22 2001-08-22 Active agent delivery systems and methods for protecting and administering active agents

Publications (1)

Publication Number Publication Date
IL154583A0 true IL154583A0 (en) 2003-09-17

Family

ID=24578160

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15458301A IL154583A0 (en) 2000-08-22 2001-08-22 Active agent delivery systems and methods for protecting and administering active agents

Country Status (6)

Country Link
US (3) US6716452B1 (xx)
EP (1) EP1311242B1 (xx)
AU (2) AU8659901A (xx)
CA (1) CA2420590A1 (xx)
IL (1) IL154583A0 (xx)
WO (1) WO2002034237A1 (xx)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US20070060500A1 (en) * 2000-08-22 2007-03-15 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
US20090306228A1 (en) * 2000-11-14 2009-12-10 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US8394813B2 (en) * 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
JP2006516948A (ja) * 2000-11-14 2006-07-13 ニュー リバー ファーマシューティカルズ インコーポレイテッド 硫酸アバカビルを含有する新規な薬剤化合物および同化合物の製造ならびに使用方法
EP1357928B1 (en) * 2000-11-16 2011-11-16 Shire LLC A novel pharmaceutical compound and methods of making and using same
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
JP2005527505A (ja) * 2002-02-22 2005-09-15 ニュー リバー ファーマシューティカルズ インコーポレイテッド 薬物血清レベルの患者間変動性を低減するためのペプチド−薬物複合体の使用
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
KR100822498B1 (ko) * 2002-02-22 2008-04-16 샤이어 엘엘씨 규제된 물질의 남용을 방지하기 위한 새로운 서방성 약학화합물
JP4625637B2 (ja) * 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US20040156844A1 (en) * 2002-05-22 2004-08-12 Curtis Wright Tamper resistant oral dosage form
AU2003232146B2 (en) * 2002-06-11 2009-06-18 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2004041208A2 (en) * 2002-11-05 2004-05-21 New River Pharmaceuticals Inc. Controlled absorption of mixed thyroyd hormone formulations
WO2004052841A1 (en) 2002-12-06 2004-06-24 Xenoport, Inc. Carbidopa prodrugs and uses thereof
US8133881B2 (en) * 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
AU2004232314B2 (en) 2003-04-22 2007-11-22 Ipsen Pharma S.A.S. Peptide vectors
NZ544162A (en) * 2003-05-29 2008-09-26 Shire Llc Abuse resistant amphetamine compounds
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
KR100915284B1 (ko) * 2003-09-30 2009-09-03 샤이어 엘엘씨 과용 또는 남용을 예방하기 위한 제약 조성물
US7176185B2 (en) * 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
DE602005015174D1 (de) * 2004-04-21 2009-08-13 Teva Pharma Verfahren zur herstellung von montelukast-natrium
EP1812040A4 (en) * 2004-11-08 2010-05-05 Shire Llc SYNERGISTIC EFFECTS OF COMBINED ADMINISTRATION OF MIRTAZAPINE AND STIMULANT COMPOUND
CA2587514A1 (en) * 2004-12-03 2006-06-08 Adherex Technologies, Inc. Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
US20070122843A1 (en) * 2005-09-23 2007-05-31 Fazlul Sarkar Isoflavonoid analogs and their metal complexes as anti-cancer agents
BRPI0619436A2 (pt) * 2005-12-05 2011-10-04 Nitto Denko Corp métodos e conjugados de aminoácido-poliglutamato
CA2643892A1 (en) 2006-02-24 2007-09-07 Shire Llc Antidepressant prodrugs
US8524663B2 (en) * 2006-03-03 2013-09-03 New York University Method for site-specific polyvalent display on polymers
CA2649360A1 (en) * 2006-04-10 2007-10-25 Shire Llc Mono and di-substituted oxycodone compounds and compositions
CA2648659A1 (en) * 2006-04-14 2007-10-25 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
MX2008016018A (es) * 2006-06-15 2009-03-25 Cell Therapeutics Inc Sede Sec Un procedimiento para la preparacion de acido poli-alfa-glutamico y derivados del mismo.
EP1867657A1 (en) * 2006-06-15 2007-12-19 Cell Therapeutics Europe S.R.L. Process for the preparation of poly-a-glutamic acid and derivatives thereof
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
US20080253969A1 (en) * 2007-04-10 2008-10-16 Nitto Denko Corporation Multi-functional polyglutamate drug carriers
EP2155254B1 (en) * 2007-05-09 2012-11-28 Nitto Denko Corporation Polymers conjugated with platinum drugs
WO2008141110A2 (en) * 2007-05-09 2008-11-20 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
KR20100017540A (ko) * 2007-05-09 2010-02-16 닛토덴코 가부시키가이샤 소수성 화합물 및 폴리아미노산 콘쥬게이트를 포함하는 조성물
WO2008141097A2 (en) 2007-05-09 2008-11-20 Pharmacofore, Inc. Stereoisomers propofol therapeutic compounds
EP2152651B1 (en) 2007-05-09 2012-01-04 Pharmacofore, Inc. Therapeutic compounds
CA2698812A1 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
EP2262474B1 (en) * 2008-01-30 2019-07-03 Imbed Biosciences, Inc. Methods and compositions for wound healing
WO2009100441A2 (en) * 2008-02-08 2009-08-13 Impax Laboratories, Inc. Depot formulations
CN104096236A (zh) * 2008-03-06 2014-10-15 日东电工株式会社 用于治疗癌症的聚合物紫杉醇结合物和方法
RU2010146489A (ru) 2008-04-16 2012-05-27 Момента Фармасьютикалз, Инк. (Us) Анализ композиций сополимера аминокислот
SG176464A1 (en) * 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
KR101123292B1 (ko) * 2008-09-26 2012-03-19 주식회사 엘지생명과학 몬테루카스트 나트륨염의 제조방법
WO2010065362A1 (en) * 2008-11-25 2010-06-10 Innovative Technologies, L.L.C. Improvements in polypeptide synthesis for drug delivery
AU2009327322A1 (en) 2008-12-19 2011-06-30 Pinnacle Pharmaceuticals, Inc. Phenazopyridine compounds
HUE033388T2 (en) 2009-05-19 2017-12-28 Neuroderm Ltd Compositions for continuous introduction of dopa decarboxylase inhibitors
US20120270847A1 (en) 2009-07-17 2012-10-25 Shire Llc Novel carbamate amino acid and peptide prodrugs of opiates and uses thereof
AU2010306698B2 (en) * 2009-10-14 2016-05-26 Adherex Technologies, Inc. Treating neurotoxicity associated with combinations of 5 - FU or its prodrugs and DPD inhibitors
JP6184101B2 (ja) * 2009-12-23 2017-08-23 サンフォード−バーナム メディカル リサーチ インスティテュート アネキシン１結合化合物に関する方法および組成物
WO2011100425A2 (en) * 2010-02-10 2011-08-18 Wound Engineering Llc Methods and compositions for wound healing
PL2580210T3 (pl) 2010-06-10 2017-09-29 Seragon Pharmaceuticals, Inc. Modulatory receptora estrogenowego i ich zastosowania
RU2740080C2 (ru) 2010-11-15 2021-01-11 Нейродерм Лтд Непрерывное введение l-допа, ингибиторов допа-декарбоксилазы, ингибиторов катехол-о-метилтрансферазы и предназначенные для этого композиции
EP2678320B1 (en) 2011-02-23 2018-09-19 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
TWI432204B (zh) * 2011-06-03 2014-04-01 Taiwan Hopax Chems Mfg Co Ltd 對抗自由基的醫藥組合物
EP2714096B1 (en) * 2011-06-03 2018-02-28 Ophidion Inc. Compositions and methods for transport across the blood brain barrier
US9296710B2 (en) 2011-06-17 2016-03-29 Eli Lilly And Company Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mGlu2 receptor agonist
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
EA029559B1 (ru) 2011-12-14 2018-04-30 Серагон Фармасьютикалс, Инк. Фторированные модуляторы рецепторов эстрогенов и их применение
US9526701B2 (en) 2011-12-20 2016-12-27 Keith R. Latham Sustained drug release and improved product stability using non-covalent particle coating methods
MX2014014902A (es) 2012-06-05 2015-03-04 Neuroderm Ltd Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
WO2014026329A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9765220B2 (en) 2013-08-22 2017-09-19 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015228369B2 (en) 2014-03-13 2020-05-21 Neuroderm Ltd DOPA decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US10653709B2 (en) * 2014-05-19 2020-05-19 North Carolina State University Methods of folding a graft copolymer with dual anticancer drugs and related applications
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US11084932B2 (en) 2015-02-26 2021-08-10 Sony Group Corporation Phenylethynylnaphthalene dyes and methods for their use
EP3262055A4 (en) 2015-02-26 2018-09-05 Sony Corporation Water soluble fluorescent or colored dyes comprising conjugating groups
US20190076467A1 (en) * 2015-06-09 2019-03-14 Commonwealth Scientific And Industrial Research Organisation Antiviral conjugates of polyanionic polymer and antiviral drug
CN109415574B (zh) 2016-04-01 2021-05-28 索尼公司 具有刚性间隔基团的超亮二聚体或聚合物染料
RU2762328C2 (ru) 2016-04-01 2021-12-17 Сони Корпорейшн Ультраяркие димерные или полимерные красители
JP7069033B2 (ja) 2016-04-06 2022-05-17 ソニーグループ株式会社 スペーシングリンカー基を有する超明色ダイマーまたはポリマー染料
JP7068192B2 (ja) 2016-05-10 2022-05-16 ソニーグループ株式会社 ポリマー染料およびシクロデキストリンを含む組成物、ならびにその使用
WO2017196954A1 (en) 2016-05-10 2017-11-16 Sony Corporation Ultra bright polymeric dyes with peptide backbones
EP3455300A1 (en) 2016-05-11 2019-03-20 Sony Corporation Ultra bright dimeric or polymeric dyes
US11377563B2 (en) 2016-06-06 2022-07-05 Sony Corporation Ionic polymers comprising fluorescent or colored reporter groups
WO2018022925A1 (en) 2016-07-29 2018-02-01 Sony Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
US11554194B2 (en) 2016-07-29 2023-01-17 Imbed Biosciences Inc. Methods and compositions for wound healing
US9695138B1 (en) 2016-10-17 2017-07-04 Acenda Pharma, Inc. Phenothiazine derivatives and methods of use thereof
EP3691690A1 (en) 2017-10-05 2020-08-12 Sony Corporation Programmable polymeric drugs
CN111836645A (zh) * 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
CN112041680A (zh) 2018-03-19 2020-12-04 索尼公司 二价金属用于增强荧光信号的应用
JP2021518410A (ja) 2018-03-21 2021-08-02 ソニーグループ株式会社 リンカー基を有するポリマータンデム色素
US12006438B2 (en) 2018-06-27 2024-06-11 Sony Group Corporation Polymeric dyes with linker groups comprising deoxyribose
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
MX2021002657A (es) 2018-09-14 2021-07-21 Jiangyin Usun Pharmaceutical Co Ltd Nuevos conjugados de montelukast y péptidos.
WO2020094634A1 (en) 2018-11-05 2020-05-14 Alkermes Pharma Ireland Limited Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods
WO2021062176A2 (en) 2019-09-26 2021-04-01 Sony Corporation Polymeric tandem dyes with linker groups
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
FR3122571B1 (fr) * 2021-05-10 2023-05-12 Hydro Fill Tech Compositions et leur utilisation pour rétablir la perméabilité intestinale et/ou prévenir ou lutter contre des maladies multifactorielles
WO2023215279A1 (en) * 2022-05-03 2023-11-09 Nocion Therapeutics, Inc. Compositions and methods for treatment of inflammatory bowel disease
WO2024042226A2 (en) * 2022-08-25 2024-02-29 Biosynth Gmbh Procedure for production of opioid-antagonist-releasing compounds and their use as a medicine

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US516993A (en) * 1894-03-20 Car-truck
BE636530A (xx) 1962-08-24
DE1493824A1 (de) 1964-01-27 1969-05-22 Hoffmann La Roche Verfahren zur Herstellung von Aminocarbonsaeureamiden
CH406567A (de) 1964-02-10 1966-01-31 Inventio Ag Einrichtung zur Steuerung der Sollwertgrösse während des Verzögerungsvorganges bei Aufzügen mit drehzahlgeregeltem Antrieb
GB1112347A (en) 1965-08-20 1968-05-01 Pierre Wirth Salts of organic bases with n-carbamyl-l-glutamic acid
US3846399A (en) * 1969-04-10 1974-11-05 Merck & Co Inc Process for controlled stepwise synthesis of polypeptides
US3643696A (en) * 1970-09-02 1972-02-22 Rex Chainbelt Inc Hydraulic control circuit
US3975342A (en) 1972-05-15 1976-08-17 Biological Developments, Inc. Tyrosyl-class antigenic conjugates, their preparation and antibodies raised thereto
US3884898A (en) * 1972-08-18 1975-05-20 Syva Co Normorphine derivatives bonded to proteins
US3843696A (en) 1972-09-05 1974-10-22 Syva Co Methadone analog compounds
US3878187A (en) * 1972-09-11 1975-04-15 Syva Co Polypeptide derivatives of amphetamine and analogs for immunoassays
US3998799A (en) 1973-11-02 1976-12-21 Interx Research Corporation Novel, transient pro-drug forms of l-dopa
US4040907A (en) 1974-06-20 1977-08-09 Syva Company Iodothyronine enzyme conjugates
US4025501A (en) * 1975-03-20 1977-05-24 Syva Company Polypeptide propoxyphene derivatives for immunoassay reagents
GB1592552A (en) 1976-12-10 1981-07-08 Inst Nat Sante Rech Med Pseudopeptides used as medicaments
US4356166A (en) 1978-12-08 1982-10-26 University Of Utah Time-release chemical delivery system
IL58965A (en) 1978-12-19 1982-08-31 Mars Inc Production of microcapsules
US4224316A (en) 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
DE3008265A1 (de) 1980-03-04 1981-09-17 Siemens AG, 1000 Berlin und 8000 München Verfahren zum sichtbarmachen von stationaeren waermeuebergangskoeffizientenfeldern auf photochemischem wege
US4426453A (en) 1980-09-18 1984-01-17 Amersham International Limited Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds
US4483807A (en) 1981-01-27 1984-11-20 Japan Atomic Energy Research Institute Process for producing a slow release composite
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4358604A (en) 1981-11-04 1982-11-09 Miles Laboratories, Inc. N-Aminoalkyl iodothyronine derivatives
US4427660A (en) 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
FR2526016A1 (fr) 1982-04-30 1983-11-04 Spiral Procede de preparation des iodo-thyronines et en particulier de rt3 a partir de la thyroxine, par reduction electrochimique a potentiel controle
HU185535B (en) 1982-05-25 1985-02-28 Mta Koezponti Hivatala Process for preparing new gonadoliberin derivatives
US4457907A (en) * 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
ATE42317T1 (de) 1983-07-29 1989-05-15 Henning Berlin Gmbh Voraktivierte kunststoffoberflaechen zur immobilisierung von organisch-chemischen und biologischen materialien, verfahren zur herstellung und verwendung derselben.
US4650675A (en) 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
JPS60166657A (ja) * 1984-02-10 1985-08-29 Nitto Boseki Co Ltd アルギニル−３−カルボキシ−４−ヒドロキシアニリド
DE3581471D1 (de) 1984-10-19 1991-02-28 Battelle Memorial Institute Durch mikroorganismen abbaubares polypeptid und seine verwendung fuer die fortschreitende abgabe von medikamenten.
IT1177384B (it) 1984-12-12 1987-08-26 Boeehringer Biochemia Robin Sp Prodotti dietetici granulari a base di amminoacidi e procedimento per la loro preparazione
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
GB8501372D0 (en) 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US4863735A (en) 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
IN165717B (xx) * 1986-08-07 1989-12-23 Battelle Memorial Institute
EP0318512B1 (en) 1986-08-18 1998-06-17 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US5057317A (en) 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5026827A (en) * 1988-09-02 1991-06-25 Matsushita Electric Industrial Co., Ltd. Amphetamine-protein complex as immunogen for obtaining antibodies specific to methamphetamine
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5767227A (en) 1989-11-03 1998-06-16 Lotus Biochemical Corp. Iodothyronine polymers
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5451410A (en) 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
IT1244873B (it) * 1990-09-12 1994-09-12 Depha Team Srl Derivati dell'acido 5-aminosalicilico (5-asa) per la terapia delle infiammazioni croniche intestinali
EP0477931B1 (en) * 1990-09-28 1994-08-17 Mercian Corporation Novel adriamycin derivatives
US5238714A (en) * 1990-10-02 1993-08-24 Board Of Regents, The University Of Texas System Efficient microcapsule preparation and method of use
US5863899A (en) 1991-04-01 1999-01-26 Cortech, Inc. Bradykinin antagonists
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5225204A (en) 1991-11-05 1993-07-06 Chen Jivn Ren Stable dosage of levothyroxine sodium and process of production
DE69224809T2 (de) 1991-12-30 1998-07-09 Akzo Nobel Nv Thyroaktive Zusammensetzung mit kontrollierter Freigabe
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5811127A (en) * 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
CA2096495C (en) 1992-06-16 2002-07-09 Kathy Palmer Ordonez Dual analyte immunoassay
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
GB9215780D0 (en) * 1992-07-24 1992-09-09 Univ London Pharmacy Peptide compounds
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
US6093391A (en) 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
IL107400A0 (en) 1992-11-10 1994-01-25 Cortech Inc Bradykinin antagonists
CA2150803C (en) 1992-12-02 2006-01-31 Henry Auer Controlled release growth hormone containing microspheres
US5298410A (en) 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
DE69426629T2 (de) * 1993-08-02 2001-08-02 Commw Scient Ind Res Org Therapeutische verbindung - fettsäurekonjugate
AU5722694A (en) 1993-11-05 1995-05-23 Astra Aktiebolag Novel amino acid derivatives
AU5825094A (en) 1993-11-19 1995-06-06 Astra Aktiebolag Novel dipeptide derivatives
GB9401891D0 (en) 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
DE4422911A1 (de) 1994-06-30 1996-01-04 Hoechst Ag Phosphinsäure-Derivate, deren Herstellung sowie deren Verwendung
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5910569A (en) 1994-11-22 1999-06-08 Lotus Biochemical Corporation Iodothyronine polymers
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5741705A (en) 1995-02-23 1998-04-21 Quest International Flavors & Food Ingredients Company, Division Of Indopco, Inc. Method for in vitro cell growth of eucaryotic cells using low molecular weight peptides
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
US5820881A (en) 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
DE69612093T2 (de) * 1995-06-07 2001-10-31 Joel K Swadesh Auf antigen verarbeitende zellen zielgerichtete konjugate ein polyaminosäure rückgrat und ein nicht-steroidales antiphlogistikum enthaltend
US5762909A (en) 1995-08-31 1998-06-09 General Electric Company Tumor targeting with polymeric molecules having extended conformation
EP0861073B1 (en) 1995-11-14 2004-07-28 Abbott GmbH & Co. KG Stabilized thyroid hormone preparations and methods of making same
US5851536A (en) 1995-11-22 1998-12-22 University Of Washington Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
EP0873361B1 (en) 1995-12-13 2006-11-02 The Regents Of The University Of California Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
ATE316799T1 (de) 1996-03-12 2006-02-15 Sanofi Aventis Deutschland Neuartige prodrugs für die therapie von tumoren und entzündlichen erkrankungen
WO1997033552A1 (en) 1996-03-12 1997-09-18 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
GB9606975D0 (en) 1996-04-02 1996-06-05 Univ Birmingham Anti-tumor agent
US6030941A (en) * 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5952294A (en) * 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
US6013633A (en) * 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
ES2210761T3 (es) 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
TW460478B (en) 1997-08-15 2001-10-21 Chugai Pharmaceutical Co Ltd Phenethylamine derivatives
WO1999030727A1 (en) * 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
ATE314372T1 (de) * 1998-01-29 2006-01-15 Univ Monash Therapeutische verbindungen
US6225285B1 (en) * 1998-03-11 2001-05-01 Exelixis Pharmaceuticals, Inc. Semaphorin K1
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6473669B2 (en) 1998-07-03 2002-10-29 Kimberly-Clark Worldwide, Inc. Controlling web tension, and accumulating lengths of web, by actively controlling velocity and acceleration of a festoon
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
AU771188B2 (en) 1999-03-05 2004-03-18 Shire Llc Use of protein conformation for the protection and release of chemical compounds
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2000053233A1 (en) 1999-03-10 2000-09-14 Lotus Biochemical Corporation Use of protein conformation for the protection and release of chemical compounds
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6355666B1 (en) 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
WO2003034980A2 (en) 2000-11-14 2003-05-01 New River Pharmaceuticals Inc. A novel pharmaceutical compound containing abacavir sulfate and methods of making and using same
US20020098999A1 (en) 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
AU2001296703A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
AU2002211863A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6740641B2 (en) * 2001-07-27 2004-05-25 Euro-Celtique, S.A. Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
CA2492823A1 (en) 2001-09-14 2003-03-27 Martin F. Bachmann In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AU2003210454A1 (en) * 2002-01-08 2003-07-24 New River Pharmaceuticals, Inc. Dendritic encapsulation of active agents
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
KR100822498B1 (ko) * 2002-02-22 2008-04-16 샤이어 엘엘씨 규제된 물질의 남용을 방지하기 위한 새로운 서방성 약학화합물
JP2005527505A (ja) * 2002-02-22 2005-09-15 ニュー リバー ファーマシューティカルズ インコーポレイテッド 薬物血清レベルの患者間変動性を低減するためのペプチド−薬物複合体の使用
WO2004082620A2 (en) * 2003-03-13 2004-09-30 Controlled Chemicals, Inc. Oxycodone conjugates with lower the abuse potential and extended duration of action
NZ544162A (en) * 2003-05-29 2008-09-26 Shire Llc Abuse resistant amphetamine compounds
KR100915284B1 (ko) * 2003-09-30 2009-09-03 샤이어 엘엘씨 과용 또는 남용을 예방하기 위한 제약 조성물

Also Published As

Publication number Publication date
US6716452B1 (en) 2004-04-06
US20040127397A1 (en) 2004-07-01
US20070232529A1 (en) 2007-10-04
EP1311242A4 (en) 2005-09-28
AU8659901A (en) 2002-05-06
US7427600B2 (en) 2008-09-23
AU2001286599B2 (en) 2007-06-21
CA2420590A1 (en) 2002-05-02
EP1311242A1 (en) 2003-05-21
EP1311242B1 (en) 2010-03-31
WO2002034237A1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
IL154583A0 (en) Active agent delivery systems and methods for protecting and administering active agents
IL163666A0 (en) Active agent delivery systems and methods for protecting and administering active agents
AU2003240949A1 (en) Active agent delivery systems and methods for protecting and administering active agents
LT2000095A (en) Aerosolised active agent delivery
IL143962A0 (en) Polymeric delivery agents and delivery agent compounds
EP1183068A4 (en) ENHANCED ACTIVE AGENT DELIVERY METHOD BY ELECTROPORATION
AU6475901A (en) System and method for assessing the performance of a pharmaceutical agent delivery system
AU2002225849A1 (en) Distal protection and delivery system and method
AU2001236457A1 (en) Compounds and compositions for delivering active agents
GB0216125D0 (en) Fibers providing controlled active agent delivery
HUP0104168A3 (en) Spray on bandage and drug delivery system
IL143087A0 (en) Drug delivery systems and methods
EP1392241A4 (en) SYSTEM FOR THE OSMOTIC RELEASE OF PHARMACEUTIC EFFECTIVENESS
IL142807A0 (en) Controlled delivery of active agents
AU2001284985A1 (en) Compounds and compositions for delivering active agents
EP1098673A4 (en) ACTIVE DUTY SYSTEMS
AU2001288277A1 (en) Compounds and compositions for delivering active agents
SG104943A1 (en) Absorbent article and barrier agent for absorbent article
PL339848A1 (en) Therapeutic agent against hypephosphataemia
EP1207812A4 (en) DEVICE FOR GUIDING IMPLANT AND ADMINISTERING AN AGENT
AU2002316200A1 (en) Compound and composition for delivering active agents
IL155102A0 (en) Delivery system for multi-pharmaceutical active materials at various release rates
EP1173192A4 (en) METHOD AND COMPOSITIONS FOR TARGETED MEDICINE ADMINISTRATION
HUP0301119A3 (en) Biologically active agent and drug
AU5682900A (en) Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed